Physician profile
Nancy Hsu
NPI 1265789960
$7,739.76
in general payments reported to CMS, 2019-2025
43 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what 89% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $404 · 2021: $353 · 2022: $884 · 2023: $1,947 · 2024: $1,421 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,248 · Consulting Fee: $450 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,248.46 |
| Consulting Fee | $450.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,080.07 | 2019-2025 | Nucala, Arexvy, Zejula |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,359.12 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $502.72 | 2019-2025 | Tezspire, Fasenra, Symbicort |
| Jazz Pharmaceuticals INC. | $336.24 | 2020-2025 | |
| Harmony Biosciences LLC | $289.61 | 2020-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $254.98 | 2021-2025 | Dupixent |
| Axsome Therapeutics, INC. | $254.64 | 2023-2025 | Sunosi |
| Viatris Specialty LLC | $146.91 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $146.73 | 2025 | Acthar |
| Grifols USA, LLC | $143.78 | 2019-2025 | Prolastin-C Liquid, Gamunex-C |
| Inspire Medical Systems, INC. | $142.83 | 2023-2025 | Inspire |
| Insmed, INC. | $139.01 | 2019-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $132.86 | 2023-2024 | Entyvio, Cuvitru, Gattex |
| Janssen Biotech, INC. | $122.73 | 2020-2025 | Tremfya |
| United Therapeutics Corporation | $114.98 | 2023 | Tyvaso |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $114.63 | 2023-2024 | Hizentra |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.56 | 2021-2024 | Xifaxan, Trulance |
| Electromed, INC. | $88.85 | 2022-2025 | Smartvest |
| Genentech USA, INC. | $84.61 | 2023-2025 | Xolair |
| Janssen Pharmaceuticals, INC | $81.63 | 2021-2022 | |
| Genzyme Corporation | $81.39 | 2023-2025 | |
| Lilly USA, LLC | $80.74 | 2024-2025 | Omvoh, Zepbound |
| Actelion Pharmaceuticals US, INC. | $77.39 | 2021-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $76.31 | 2025 | Ohtuvayre |
| Philips North America LLC | $72.65 | 2023-2024 | (O58) Sleep Respiratory Care Und |
| Merck Sharp & Dohme LLC | $64.57 | 2019-2024 | Dificid, Zerbaxa |
| Itamar Medical INC | $64.49 | 2022-2024 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $64.43 | 2023-2025 | Lumryz |
| Idorsia Pharmaceuticals US INC | $48.58 | 2023-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $47.96 | 2023-2024 | Horizant, Horizant |
| Baxter Healthcare | $44.98 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $44.25 | 2025 | Tezspire |
| Abbvie INC. | $43.02 | 2023-2025 | |
| Mylan Specialty L.P. | $40.37 | 2024 | Yupelri |
| Noctrix Health, INC. | $30.48 | 2025 | Nidra |
| Leo Pharma INC. | $25.72 | 2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $19.93 | 2025 | |
| Celltrion USA INC. | $19.21 | 2025 | Vegzelma |
| Pfizer INC. | $16.02 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.76 | 2021 | |
| Braintree Laboratories, INC. | $13.63 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.